HANDBOOK OF GENERAL MEDICINE VOL 1:@0.076190:0.972666:0.349932:0.972666:0.349932:0.958637:0.076190:0.958637:0.009179:0.009945:0.009945:0.009999:0.007714:0.011679:0.011679:0.007943:0.003723:0.011679:0.006518:0.003723:0.011719:0.007203:0.009945:0.007203:0.008158:0.009945:0.006209:0.003723:0.012351:0.007203:0.009999:0.003037:0.010926:0.003037:0.009945:0.007203:0.003723:0.009434:0.011679:0.006209:0.003723:0.007445
58:@0.083944:0.033217:0.104640:0.033217:0.104640:0.013052:0.083944:0.013052:0.010348:0.010348
TREATMENT AppROACHEs:@0.397030:0.032906:0.624375:0.032906:0.624375:0.013617:0.397030:0.013617:0.007872:0.011217:0.009905:0.013674:0.007872:0.016982:0.009905:0.013674:0.007872:0.005119:0.013674:0.010939:0.010939:0.011217:0.016058:0.013674:0.015023:0.012621:0.009905:0.009202
randomised control studies:@0.076190:0.284430:0.299952:0.284430:0.299952:0.266099:0.076190:0.266099:0.009743:0.011087:0.010079:0.011087:0.010751:0.015791:0.004032:0.007392:0.010751:0.011087:0.004704:0.010751:0.010751:0.010079:0.005040:0.005376:0.010751:0.004032:0.004704:0.007392:0.005040:0.010079:0.011087:0.004032:0.010751:0.007392
A number of Dpp-4 inhibitors have been studied in ran-:@0.076190:0.301482:0.480957:0.301482:0.480957:0.285699:0.076190:0.285699:0.011188:0.004853:0.009223:0.009192:0.014182:0.010311:0.009827:0.004551:0.004853:0.009903:0.004747:0.004853:0.011249:0.008950:0.008950:0.005020:0.008376:0.004868:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.004868:0.009223:0.010326:0.008376:0.009827:0.004868:0.010311:0.009827:0.009827:0.009223:0.004868:0.005866:0.005125:0.009192:0.010357:0.003024:0.009827:0.010357:0.004868:0.003024:0.009223:0.004868:0.004551:0.010326:0.009223:0.005020
domised control studies, notably saxagliptin  (sAVOR :@0.076190:0.316364:0.485130:0.316364:0.485130:0.300581:0.076190:0.300581:0.010357:0.009903:0.014182:0.003024:0.005866:0.009827:0.010357:0.009071:0.009782:0.009903:0.009223:0.005125:0.004536:0.009903:0.003024:0.009071:0.005866:0.005125:0.009192:0.010357:0.003024:0.009827:0.005866:0.004188:0.009071:0.009223:0.009903:0.005125:0.010326:0.010311:0.003024:0.008104:0.009071:0.005866:0.010326:0.007257:0.010326:0.010175:0.003024:0.003024:0.010311:0.005125:0.003024:0.009223:0.004188:0.004899:0.005579:0.007529:0.011188:0.010614:0.013138:0.009177:0.004188
TIMI-53), sitagliptin (TECOs), alogliptin (EXAMINE)  and :@0.076190:0.331246:0.485145:0.331246:0.485145:0.315463:0.076190:0.315463:0.006441:0.003417:0.013894:0.003417:0.005020:0.008376:0.008376:0.005579:0.004188:0.008331:0.005866:0.003024:0.005125:0.010326:0.010175:0.003024:0.003024:0.010311:0.005125:0.003024:0.009223:0.008331:0.005579:0.006441:0.008104:0.012292:0.013138:0.007529:0.005579:0.004188:0.008331:0.010326:0.003024:0.009903:0.010175:0.003024:0.003024:0.010311:0.005125:0.003024:0.009223:0.008331:0.005579:0.008104:0.009207:0.011188:0.013894:0.003417:0.011188:0.008104:0.005579:0.004188:0.004127:0.010326:0.009223:0.010357:0.004188
lina gliptin (CARMELINA). :@0.076190:0.346128:0.256848:0.346128:0.256848:0.330345:0.076190:0.330345:0.003024:0.003024:0.009223:0.010326:0.000000:0.010175:0.003024:0.003024:0.010311:0.005125:0.003024:0.009223:0.004188:0.005579:0.012292:0.011188:0.009177:0.013894:0.008104:0.006985:0.003417:0.011188:0.011188:0.005579:0.004188:0.004188
Table 2 summarises abstracts of these studies::@0.090478:0.361010:0.422038:0.361010:0.422038:0.345227:0.090478:0.345227:0.006441:0.010326:0.010311:0.003024:0.009827:0.004188:0.008376:0.004188:0.005866:0.009192:0.014182:0.014182:0.010326:0.004551:0.003024:0.005866:0.009827:0.005866:0.004188:0.010326:0.010311:0.005866:0.005125:0.004551:0.010326:0.009782:0.005125:0.005866:0.004188:0.009903:0.004747:0.004188:0.005125:0.009223:0.009827:0.005866:0.009827:0.004188:0.005866:0.005125:0.009192:0.010357:0.003024:0.009827:0.005866:0.004188
sAvOr-TIMI 53:@0.076190:0.391282:0.183233:0.391282:0.183233:0.374784:0.076190:0.374784:0.007862:0.011188:0.010583:0.012700:0.008769:0.006350:0.006350:0.004233:0.013607:0.004233:0.004233:0.008467:0.008467
 :@0.183218:0.391282:0.187451:0.391282:0.187451:0.374784:0.183218:0.374784:0.004233
(saxagliptin assessment of vascular outcomes recorded :@0.076190:0.408727:0.485145:0.408727:0.485145:0.392945:0.076190:0.392945:0.005579:0.007529:0.010326:0.007257:0.010326:0.010175:0.003024:0.003024:0.010311:0.005125:0.003024:0.009223:0.003810:0.010326:0.005866:0.005866:0.009827:0.005866:0.005866:0.014182:0.009827:0.009223:0.005125:0.003765:0.009903:0.004747:0.003750:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.003765:0.009903:0.009192:0.005125:0.009782:0.009903:0.014182:0.009827:0.005866:0.003750:0.004551:0.009827:0.009782:0.009903:0.004551:0.010357:0.009827:0.010357:0.004188
 :@0.161129:0.408727:0.165362:0.408727:0.165362:0.392229:0.161129:0.392229:0.004233
in patients with diabetes mellitus-thrombolysis in myo-:@0.076190:0.423609:0.480957:0.423609:0.480957:0.407827:0.076190:0.407827:0.003024:0.009223:0.007045:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.007045:0.012564:0.003024:0.005125:0.009223:0.007045:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.007045:0.014182:0.009827:0.003024:0.003024:0.003024:0.005125:0.009192:0.005866:0.005020:0.005125:0.009223:0.004551:0.009903:0.014182:0.010311:0.009903:0.003024:0.008104:0.005866:0.003024:0.005866:0.007045:0.003024:0.009223:0.007045:0.014182:0.008104:0.009903:0.005020
cardial infarction):@0.076190:0.438491:0.206275:0.438491:0.206275:0.422709:0.076190:0.422709:0.009782:0.010326:0.004551:0.010357:0.003024:0.010326:0.003024:0.004188:0.003024:0.009223:0.004747:0.010326:0.004551:0.009782:0.005125:0.003024:0.009903:0.009223:0.005579
 :@0.206275:0.438491:0.210508:0.438491:0.210508:0.421993:0.206275:0.421993:0.004233
primary endpoint:  saxagliptin neither  reduced  nor :@0.090478:0.453373:0.485160:0.453373:0.485160:0.437591:0.090478:0.437591:0.008950:0.004551:0.003024:0.014182:0.010326:0.004551:0.008104:0.009585:0.009827:0.009223:0.010357:0.010311:0.009903:0.003024:0.009223:0.005125:0.004188:0.004188:0.005397:0.007529:0.010326:0.007257:0.010326:0.010175:0.003024:0.003024:0.010311:0.005125:0.003024:0.009238:0.009585:0.009223:0.009827:0.003024:0.005125:0.009223:0.009827:0.004551:0.004188:0.005382:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.010357:0.004188:0.005382:0.009223:0.009903:0.004551:0.004188
increased risk of  primary endpoint  of  cardiovascular :@0.076190:0.468256:0.485130:0.468256:0.485130:0.452473:0.076190:0.452473:0.003024:0.009223:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.010357:0.008376:0.004551:0.003024:0.005866:0.007590:0.008376:0.009903:0.004747:0.004188:0.004173:0.010311:0.004551:0.003024:0.014182:0.010326:0.004551:0.008104:0.008376:0.009827:0.009223:0.010357:0.010311:0.009903:0.003024:0.009223:0.005125:0.004188:0.004173:0.009903:0.004747:0.004188:0.004173:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.004188
death, non-fatal MI or non-fatal ischaemic stroke, when :@0.076190:0.483138:0.485145:0.483138:0.485145:0.467355:0.076190:0.467355:0.010357:0.009827:0.010326:0.005125:0.009223:0.004188:0.003886:0.009223:0.009903:0.009223:0.005020:0.004747:0.010326:0.005125:0.010326:0.003024:0.003886:0.013894:0.003417:0.003886:0.009903:0.004551:0.003886:0.009223:0.009903:0.009223:0.005020:0.004747:0.010326:0.005125:0.010326:0.003024:0.003886:0.003024:0.005866:0.009782:0.009223:0.010326:0.009827:0.014182:0.003024:0.009782:0.003901:0.005866:0.005125:0.004551:0.009903:0.007590:0.009827:0.004188:0.003870:0.012564:0.009223:0.009827:0.009223:0.004188
compared to placebo. Although there  was no differ-:@0.076190:0.498020:0.480957:0.498020:0.480957:0.482237:0.076190:0.482237:0.009782:0.009903:0.014182:0.010311:0.010326:0.004551:0.009827:0.010357:0.006728:0.005125:0.009903:0.006728:0.010311:0.003024:0.010326:0.009782:0.009827:0.010311:0.009903:0.004188:0.006728:0.011188:0.003024:0.005125:0.009223:0.009888:0.009192:0.010175:0.009223:0.006728:0.005125:0.009223:0.009827:0.004551:0.009827:0.004188:0.002525:0.012564:0.010326:0.005866:0.006728:0.009223:0.009903:0.006728:0.010357:0.003024:0.004747:0.004747:0.009827:0.004551:0.005020
ence between treatments  for secondary endpoint, :@0.519042:0.084958:0.928012:0.084958:0.928012:0.069176:0.519042:0.069176:0.009827:0.009223:0.009782:0.009827:0.010387:0.010311:0.009827:0.005125:0.012564:0.009827:0.009827:0.009223:0.010387:0.005125:0.004551:0.009827:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.005866:0.004188:0.006184:0.004747:0.009903:0.004551:0.010387:0.005866:0.009827:0.009782:0.009903:0.009223:0.010357:0.010326:0.004551:0.008104:0.010387:0.009827:0.009223:0.010357:0.010311:0.009903:0.003024:0.009223:0.005125:0.004188:0.004188
there was an :@0.519042:0.099228:0.622048:0.099228:0.622048:0.083446:0.519042:0.083446:0.005125:0.009223:0.009827:0.004551:0.009827:0.005972:0.012564:0.010326:0.005866:0.005987:0.010326:0.009223:0.004188
increased risk of hospitalisation for heart :@0.623847:0.099228:0.927997:0.099228:0.927997:0.083446:0.623847:0.083446:0.003024:0.009223:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.010357:0.005987:0.004551:0.003024:0.005866:0.007590:0.005987:0.009903:0.004747:0.005987:0.009223:0.009903:0.005866:0.010311:0.003024:0.005125:0.010326:0.003024:0.003024:0.005866:0.010326:0.005125:0.003024:0.009918:0.009223:0.005987:0.004747:0.009903:0.004551:0.005987:0.009223:0.009827:0.010326:0.004551:0.005125:0.004188
failure:@0.519042:0.113499:0.563734:0.113499:0.563734:0.097716:0.519042:0.097716:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827
 with the use of saxagliptin.:@0.563734:0.113499:0.760191:0.113499:0.760191:0.097716:0.563734:0.097716:0.004188:0.012564:0.003024:0.005125:0.009223:0.004188:0.005125:0.009223:0.009827:0.004188:0.009192:0.005866:0.009827:0.004188:0.009903:0.004747:0.004188:0.005866:0.010326:0.007257:0.010326:0.010175:0.003024:0.003024:0.010311:0.005125:0.003024:0.009223:0.004188
7:@0.760184:0.108162:0.765042:0.108162:0.765042:0.099008:0.760184:0.099008:0.004858
TeCOs:@0.519047:0.143119:0.565614:0.143119:0.565614:0.126621:0.519047:0.126621:0.006350:0.007862:0.011793:0.012700:0.007862
 :@0.565614:0.143119:0.569847:0.143119:0.569847:0.126621:0.565614:0.126621:0.004233
(Trial evaluating  cardiovascular outcomes  with  sita-:@0.519047:0.159953:0.923784:0.159953:0.923784:0.144170:0.519047:0.144170:0.005579:0.006441:0.004551:0.003024:0.010326:0.003024:0.010236:0.009827:0.008376:0.010326:0.003024:0.009192:0.010326:0.005125:0.003024:0.009223:0.010175:0.004188:0.005927:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.010130:0.009903:0.009192:0.005125:0.009782:0.009903:0.014182:0.009827:0.005866:0.004188:0.005927:0.012564:0.003024:0.005125:0.009223:0.004188:0.005927:0.005866:0.003024:0.005125:0.010326:0.005020
 :@0.551992:0.159953:0.556225:0.159953:0.556225:0.143454:0.551992:0.143454:0.004233
gliptin):@0.519047:0.174223:0.568532:0.174223:0.568532:0.158440:0.519047:0.158440:0.010175:0.003024:0.003024:0.010311:0.005125:0.003024:0.009223:0.005579
sitagliptin did not affect rates of 3-point MACE :@0.533335:0.188493:0.927972:0.188493:0.927972:0.172710:0.533335:0.172710:0.007680:0.003175:0.005277:0.010477:0.010326:0.003175:0.003175:0.010462:0.005277:0.003175:0.009374:0.010735:0.010508:0.003175:0.010508:0.010735:0.009374:0.010054:0.005277:0.010735:0.010477:0.004899:0.004899:0.009979:0.009933:0.005277:0.010735:0.004702:0.010477:0.005277:0.009979:0.006017:0.010735:0.010054:0.004899:0.010735:0.008527:0.005171:0.010462:0.010054:0.003175:0.009374:0.005277:0.010735:0.014046:0.011339:0.012443:0.008104:0.004188
(death from any cause, cardiovascular death, or non-:@0.519047:0.202763:0.923829:0.202763:0.923829:0.186980:0.519047:0.186980:0.005730:0.010508:0.009979:0.010477:0.005277:0.009374:0.004460:0.004899:0.004702:0.010054:0.014333:0.004460:0.010477:0.009374:0.008255:0.004460:0.009933:0.010477:0.009344:0.006017:0.009979:0.004339:0.004460:0.009933:0.010477:0.004702:0.010508:0.003175:0.010054:0.008527:0.010477:0.006017:0.009933:0.009344:0.003175:0.010477:0.004702:0.004460:0.010508:0.009979:0.010477:0.005277:0.009374:0.004339:0.004460:0.010054:0.004702:0.004460:0.009374:0.010054:0.009374:0.005020
cardiovascular death), compared to placebo. Also, :@0.519047:0.217033:0.928032:0.217033:0.928032:0.201251:0.519047:0.201251:0.009933:0.010477:0.004702:0.010508:0.003175:0.010054:0.008527:0.010477:0.006017:0.009933:0.009344:0.003175:0.010477:0.004702:0.007635:0.010508:0.009979:0.010477:0.005277:0.009374:0.005730:0.004339:0.007635:0.009933:0.010054:0.014333:0.010462:0.010477:0.004702:0.009979:0.010508:0.007635:0.005277:0.010054:0.007635:0.010462:0.003175:0.010477:0.009933:0.009979:0.010462:0.010054:0.004339:0.007635:0.011339:0.003175:0.006017:0.010054:0.004188:0.004188
there  was no increase in rates of hospitalisation for :@0.519047:0.231303:0.928047:0.231303:0.928047:0.215521:0.519047:0.215521:0.005277:0.009374:0.009979:0.004702:0.009979:0.004188:0.003825:0.012715:0.010477:0.006017:0.008028:0.009374:0.010054:0.008028:0.003175:0.009374:0.009933:0.004702:0.009979:0.010477:0.006017:0.009979:0.008028:0.003175:0.009374:0.008028:0.004702:0.010477:0.005277:0.009979:0.006017:0.008028:0.010054:0.004899:0.008028:0.009374:0.010054:0.006017:0.010462:0.003175:0.005277:0.010477:0.003175:0.003175:0.006017:0.010477:0.005277:0.003175:0.010054:0.009374:0.008028:0.004899:0.010054:0.004551:0.004188
heart failure.  :@0.519047:0.245574:0.622321:0.245538:0.622321:0.229755:0.519047:0.229791:0.009374:0.009979:0.010477:0.004702:0.005277:0.004339:0.004899:0.010477:0.003175:0.003175:0.009344:0.004702:0.009979:0.004188:0.005000:0.390521
8:@0.613273:0.240239:0.618131:0.240239:0.618131:0.231085:0.613273:0.231085:0.004858
eXAMINe:@0.519043:0.275198:0.585264:0.275198:0.585264:0.258700:0.519043:0.258700:0.007862:0.010281:0.011188:0.013607:0.004233:0.011188:0.007862
 :@0.585249:0.275198:0.589483:0.275198:0.589483:0.258700:0.585249:0.258700:0.004233
(Examination of cardiovascular outcomes with aloglip-:@0.519043:0.292031:0.923795:0.292031:0.923795:0.276249:0.519043:0.276249:0.005579:0.008104:0.007257:0.010326:0.014182:0.003024:0.009223:0.010326:0.005125:0.003024:0.009903:0.009223:0.005382:0.009903:0.004747:0.005382:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.005382:0.009903:0.009192:0.005125:0.009782:0.009903:0.014182:0.009827:0.005866:0.005367:0.012564:0.003024:0.005125:0.009223:0.005382:0.010326:0.003024:0.009903:0.010175:0.003024:0.003024:0.010311:0.005020
tin :@0.519043:0.306302:0.540603:0.306302:0.540603:0.290519:0.519043:0.290519:0.005125:0.003024:0.009223:0.004188
versus:@0.540603:0.306302:0.584282:0.306302:0.584282:0.290519:0.540603:0.290519:0.008376:0.009827:0.004551:0.005866:0.009192:0.005866
 standard of care):@0.584282:0.306302:0.717692:0.306302:0.717692:0.290519:0.584282:0.290519:0.004188:0.005866:0.005125:0.010326:0.009223:0.010357:0.010326:0.004551:0.010357:0.004188:0.009903:0.004747:0.004188:0.009782:0.010326:0.004551:0.009827:0.005579
Alogliptin showed similar rates of the primary compos-:@0.533330:0.320572:0.923795:0.320572:0.923795:0.304789:0.533330:0.304789:0.011188:0.003024:0.009903:0.010175:0.003024:0.003024:0.010311:0.005125:0.003024:0.009223:0.003734:0.005866:0.009223:0.009903:0.012564:0.009827:0.010357:0.003734:0.005866:0.003024:0.014182:0.003024:0.003024:0.010326:0.004551:0.003750:0.004551:0.010326:0.005125:0.009827:0.005866:0.003734:0.009903:0.004747:0.003734:0.005125:0.009223:0.009827:0.003734:0.010311:0.004551:0.003024:0.014182:0.010326:0.004551:0.008104:0.003750:0.009782:0.009903:0.014182:0.010311:0.009903:0.005866:0.005020
ite endpoint  of cardiovascular death,  non-fatal  myo-:@0.519043:0.334842:0.923810:0.334842:0.923810:0.319059:0.519043:0.319059:0.003024:0.005125:0.009827:0.007106:0.009827:0.009223:0.010357:0.010311:0.009903:0.003024:0.009223:0.005125:0.004188:0.002903:0.009903:0.004747:0.007106:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.007106:0.010357:0.009827:0.010326:0.005125:0.009223:0.004188:0.004188:0.002903:0.009223:0.009903:0.009223:0.005020:0.004747:0.010326:0.005125:0.010326:0.003024:0.004188:0.002903:0.014182:0.008104:0.009903:0.005020
cardial  infarction or non-fatal ischaemic  stroke, com-:@0.519043:0.349112:0.923825:0.349112:0.923825:0.333330:0.519043:0.333330:0.009782:0.010326:0.004551:0.010357:0.003024:0.010326:0.003024:0.004188:0.002842:0.003024:0.009223:0.004747:0.010326:0.004551:0.009782:0.005125:0.003024:0.009903:0.009223:0.007015:0.009903:0.004551:0.007015:0.009223:0.009903:0.009223:0.005020:0.004747:0.010326:0.005125:0.010326:0.003024:0.007015:0.003024:0.005866:0.009782:0.009223:0.010326:0.009827:0.014182:0.003024:0.009782:0.004188:0.002842:0.005866:0.005125:0.004551:0.009903:0.007590:0.009827:0.004188:0.007015:0.009782:0.009903:0.014182:0.005020
pared to placebo. There was an increased tendency :@0.519043:0.363382:0.927983:0.363382:0.927983:0.347600:0.519043:0.347600:0.010311:0.010326:0.004551:0.009827:0.010357:0.006320:0.005125:0.009903:0.006320:0.010311:0.003024:0.010326:0.009782:0.009827:0.010311:0.009903:0.004188:0.006320:0.006441:0.009223:0.009827:0.004551:0.009827:0.006320:0.012564:0.010326:0.005866:0.006335:0.010326:0.009223:0.006320:0.003024:0.009223:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.010357:0.006320:0.005125:0.009827:0.009223:0.010357:0.009827:0.009223:0.009782:0.008104:0.004188
towards heart failure, as compared to placebo, but this :@0.519043:0.377653:0.927983:0.377653:0.927983:0.361870:0.519043:0.361870:0.005125:0.009903:0.012564:0.010326:0.004551:0.010357:0.005866:0.004022:0.009223:0.009827:0.010326:0.004551:0.005125:0.004007:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.004188:0.004022:0.010326:0.005866:0.004022:0.009782:0.009903:0.014182:0.010311:0.010326:0.004551:0.009827:0.010357:0.004007:0.005125:0.009903:0.004007:0.010311:0.003024:0.010326:0.009782:0.009827:0.010311:0.009903:0.004188:0.004022:0.010311:0.009192:0.005125:0.004022:0.005125:0.009223:0.003024:0.005866:0.004188
was not statistically significant.:@0.519043:0.391923:0.739675:0.391923:0.739675:0.376140:0.519043:0.376140:0.012564:0.010326:0.005866:0.004188:0.009223:0.009903:0.005125:0.004188:0.005866:0.005125:0.010326:0.005125:0.003024:0.005866:0.005125:0.003024:0.009782:0.010326:0.003024:0.003024:0.008104:0.004188:0.005866:0.003024:0.010175:0.009223:0.003024:0.003681:0.003681:0.009782:0.010326:0.009223:0.005125:0.004188
9:@0.739683:0.386581:0.744541:0.386581:0.744541:0.377427:0.739683:0.377427:0.004858
CArMeLINA:@0.519047:0.421539:0.605528:0.421539:0.605528:0.405040:0.519047:0.405040:0.011793:0.011188:0.008769:0.013607:0.007862:0.006652:0.004233:0.011188:0.011188
 :@0.605513:0.421539:0.609746:0.421539:0.609746:0.405040:0.605513:0.405040:0.004233
(Cardiovascular and renal  microvascular outcome :@0.519047:0.438880:0.928002:0.438880:0.928002:0.423097:0.519047:0.423097:0.005579:0.012292:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.012413:0.010326:0.009223:0.010357:0.012413:0.004551:0.009827:0.009223:0.010326:0.003024:0.004188:0.008210:0.014182:0.003024:0.009782:0.004551:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.012413:0.009903:0.009192:0.005125:0.009782:0.009903:0.014182:0.009827:0.004188
study with linagliptin in patients with type 2 diabetes :@0.519047:0.453658:0.928002:0.453658:0.928002:0.437875:0.519047:0.437875:0.005866:0.005125:0.009192:0.010357:0.008104:0.007408:0.012564:0.003024:0.005125:0.009223:0.007408:0.003024:0.003024:0.009223:0.010326:0.010175:0.003024:0.003024:0.010311:0.005125:0.003024:0.009223:0.007408:0.003024:0.009223:0.007408:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.007408:0.012564:0.003024:0.005125:0.009223:0.007408:0.005125:0.008104:0.010311:0.009827:0.007408:0.008376:0.007408:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.004188
mellitus):@0.519047:0.468436:0.577890:0.468436:0.577890:0.452654:0.519047:0.452654:0.014182:0.009827:0.003024:0.003024:0.003024:0.005125:0.009192:0.005866:0.005579
Linagliptin showed  similar rates  of  the  primary  com-:@0.533335:0.483214:0.923799:0.483214:0.923799:0.467432:0.533335:0.467432:0.006985:0.003024:0.009223:0.010326:0.010175:0.003024:0.003024:0.010311:0.005125:0.003024:0.009223:0.006698:0.005866:0.009223:0.009903:0.012564:0.009827:0.010357:0.004188:0.002495:0.005866:0.003024:0.014182:0.003024:0.003024:0.010326:0.004551:0.006698:0.004551:0.010326:0.005125:0.009827:0.005866:0.004188:0.002495:0.009903:0.004747:0.004188:0.002495:0.005125:0.009223:0.009827:0.004188:0.002495:0.010311:0.004551:0.003024:0.014182:0.010326:0.004551:0.008104:0.004188:0.002495:0.009782:0.009903:0.014182:0.005020
posite endpoint of cardiovascular death, non-fatal MI, :@0.519047:0.497993:0.928002:0.497993:0.928002:0.482210:0.519047:0.482210:0.010311:0.009903:0.005866:0.003024:0.005125:0.009827:0.005367:0.009827:0.009223:0.010357:0.010311:0.009903:0.003024:0.009223:0.005125:0.005367:0.009903:0.004747:0.005367:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.005382:0.010357:0.009827:0.010326:0.005125:0.009223:0.004188:0.005367:0.009223:0.009903:0.009223:0.005020:0.004747:0.010326:0.005125:0.010326:0.003024:0.005367:0.013894:0.003417:0.004188:0.004188
teCOs:@0.215825:0.545352:0.257218:0.545352:0.257218:0.530687:0.215825:0.530687:0.005644:0.006988:0.010483:0.011289:0.006988
sAVOr-timi:@0.393867:0.545352:0.470201:0.545352:0.470201:0.530687:0.393867:0.530687:0.006988:0.009945:0.009407:0.011289:0.007795:0.005644:0.005644:0.003763:0.012095:0.003763
exAmine:@0.571909:0.545352:0.630772:0.545352:0.630772:0.530687:0.571909:0.530687:0.006988:0.009139:0.009945:0.012095:0.003763:0.009945:0.006988
CArmelinA:@0.749951:0.545352:0.826823:0.545352:0.826823:0.530687:0.749951:0.530687:0.010483:0.009945:0.007795:0.012095:0.006988:0.005913:0.003763:0.009945:0.009945
medication:@0.082052:0.560746:0.156236:0.560746:0.156236:0.546081:0.082052:0.546081:0.012095:0.008601:0.008870:0.003225:0.008601:0.008870:0.004032:0.003225:0.008601:0.008063
sitagliptin:@0.215812:0.560746:0.277954:0.560746:0.277954:0.546717:0.215812:0.546717:0.006693:0.002688:0.004556:0.009179:0.009045:0.002688:0.002688:0.009165:0.004556:0.002688:0.008198
8:@0.277975:0.556036:0.282293:0.556036:0.282293:0.547899:0.277975:0.547899:0.004318
saxagliptin:@0.393871:0.560746:0.464400:0.560746:0.464400:0.546717:0.393871:0.546717:0.006693:0.009179:0.006451:0.009179:0.009045:0.002688:0.002688:0.009165:0.004556:0.002688:0.008198
7:@0.464407:0.556036:0.468725:0.556036:0.468725:0.547899:0.464407:0.547899:0.004318
Alogliptin:@0.571917:0.560746:0.632380:0.560746:0.632380:0.546717:0.571917:0.546717:0.009945:0.002688:0.008803:0.009045:0.002688:0.002688:0.009165:0.004556:0.002688:0.008198
9:@0.632380:0.556036:0.636698:0.556036:0.636698:0.547899:0.632380:0.547899:0.004318
Linagliptin:@0.749963:0.560746:0.815264:0.560746:0.815264:0.546717:0.749963:0.546717:0.006209:0.002688:0.008198:0.009179:0.009045:0.002688:0.002688:0.009165:0.004556:0.002688:0.008198
10:@0.815269:0.556036:0.823905:0.556036:0.823905:0.547899:0.815269:0.547899:0.004318:0.004318
# of patients:@0.082070:0.576140:0.161630:0.576140:0.161630:0.561475:0.082070:0.561475:0.008063:0.003763:0.008601:0.003763:0.003763:0.008870:0.008870:0.004032:0.003225:0.008601:0.008063:0.004032:0.005913
14 671:@0.215830:0.576140:0.256779:0.576140:0.256779:0.562111:0.215830:0.562111:0.007445:0.007445:0.003723:0.007445:0.007445:0.007445
16 492:@0.393872:0.576140:0.434821:0.576140:0.434821:0.562111:0.393872:0.562111:0.007445:0.007445:0.003723:0.007445:0.007445:0.007445
5 380:@0.571913:0.576140:0.605417:0.576140:0.605417:0.562111:0.571913:0.562111:0.007445:0.003723:0.007445:0.007445:0.007445
8 300:@0.749955:0.576140:0.783459:0.576140:0.783459:0.562111:0.749955:0.562111:0.007445:0.003723:0.007445:0.007445:0.007445
History:@0.082057:0.591534:0.125062:0.591534:0.125062:0.576868:0.082057:0.576868:0.009139:0.003225:0.005913:0.004032:0.008601:0.004301:0.007795
DM2, established CVD:@0.215816:0.591534:0.360717:0.591534:0.360717:0.577505:0.215816:0.577505:0.009999:0.012351:0.007445:0.003723:0.003723:0.008735:0.005214:0.004556:0.009179:0.009165:0.002688:0.002688:0.005214:0.008198:0.008735:0.009206:0.003723:0.010926:0.009434:0.009999
DM2, established CVD or  DM2, recent acute :@0.393858:0.591534:0.698886:0.591534:0.698886:0.577505:0.393858:0.577505:0.009999:0.012351:0.007445:0.003723:0.003723:0.008735:0.005214:0.004556:0.009179:0.009165:0.002688:0.002688:0.005214:0.008198:0.008735:0.009206:0.003723:0.010926:0.009434:0.009999:0.003723:0.008803:0.004045:0.003723:0.012848:0.009999:0.012351:0.007445:0.003723:0.003723:0.004045:0.008735:0.008695:0.008735:0.008198:0.004556:0.003723:0.009179:0.008695:0.008171:0.004556:0.008735:0.003723
multiple risk factors:@0.393858:0.604362:0.516007:0.604362:0.516007:0.590333:0.393858:0.590333:0.012606:0.008171:0.002688:0.004556:0.002688:0.009165:0.002688:0.008735:0.003723:0.004045:0.002688:0.005214:0.006746:0.003723:0.004220:0.009179:0.008695:0.004556:0.008803:0.004045:0.005214
coronary syndrome event events, BMI  45:@0.571900:0.604362:0.850152:0.604362:0.850152:0.590333:0.571900:0.590333:0.008695:0.008803:0.004045:0.008803:0.008198:0.009179:0.004045:0.007203:0.003655:0.005214:0.007203:0.008198:0.009206:0.004045:0.008803:0.012606:0.008735:0.003669:0.008735:0.007445:0.008735:0.008198:0.004556:0.010087:0.008735:0.007445:0.008735:0.008198:0.004556:0.005214:0.003723:0.003723:0.007714:0.012351:0.003037:0.003723:0.008144:0.007445:0.007445
DM2, high risk for CV :@0.749963:0.591534:0.886343:0.591534:0.886343:0.577505:0.749963:0.577505:0.009999:0.012351:0.007445:0.003723:0.003723:0.008198:0.002688:0.009045:0.008198:0.003723:0.004045:0.002688:0.005214:0.006746:0.003723:0.004220:0.008803:0.004045:0.003723:0.010926:0.009434:0.003723
<:@0.827117:0.604362:0.835261:0.604362:0.835261:0.590333:0.827117:0.590333:0.008144
study design:@0.082064:0.619756:0.165118:0.619756:0.165118:0.605091:0.082064:0.605091:0.006988:0.004032:0.008063:0.008870:0.007795:0.003763:0.008870:0.008601:0.005913:0.003225:0.008870:0.008063
Multi-centre, randomised,  Multi-centre, randomised,  Multi-centre, randomised,  Multi-centre, randomised, :@0.215824:0.619756:0.920600:0.619756:0.920600:0.605727:0.215824:0.605727:0.012351:0.008171:0.002688:0.004556:0.002688:0.004462:0.008695:0.008735:0.008198:0.004556:0.004045:0.008735:0.003723:0.003723:0.004045:0.009179:0.008198:0.009206:0.008803:0.012606:0.002688:0.005214:0.008735:0.009206:0.003723:0.003723:0.007392:0.012351:0.008171:0.002688:0.004556:0.002688:0.004462:0.008695:0.008735:0.008198:0.004556:0.004045:0.008735:0.003723:0.003723:0.004045:0.009179:0.008198:0.009206:0.008803:0.012606:0.002688:0.005214:0.008735:0.009206:0.003723:0.003723:0.007392:0.012351:0.008171:0.002688:0.004556:0.002688:0.004462:0.008695:0.008735:0.008198:0.004556:0.004045:0.008735:0.003723:0.003723:0.004045:0.009179:0.008198:0.009206:0.008803:0.012606:0.002688:0.005214:0.008735:0.009206:0.003723:0.003723:0.007392:0.012351:0.008171:0.002688:0.004556:0.002688:0.004462:0.008695:0.008735:0.008198:0.004556:0.004045:0.008735:0.003723:0.003723:0.004045:0.009179:0.008198:0.009206:0.008803:0.012606:0.002688:0.005214:0.008735:0.009206:0.003723:0.003723
double-blind, open label:@0.215824:0.632584:0.377524:0.632584:0.377524:0.618555:0.215824:0.618555:0.009206:0.008803:0.008171:0.009165:0.002688:0.008735:0.004462:0.009165:0.002688:0.002688:0.008198:0.009206:0.003723:0.003723:0.008803:0.009165:0.008735:0.008198:0.003723:0.002688:0.009179:0.009165:0.008735:0.002688
double-blind, placebo-:@0.393866:0.632584:0.545379:0.632584:0.545379:0.618555:0.393866:0.618555:0.009206:0.008803:0.008171:0.009165:0.002688:0.008735:0.004462:0.009165:0.002688:0.002688:0.008198:0.009206:0.003723:0.003723:0.009165:0.002688:0.009179:0.008695:0.008735:0.009165:0.008803:0.004462
controlled:@0.393866:0.645412:0.460282:0.645412:0.460282:0.631383:0.393866:0.631383:0.008695:0.008803:0.008198:0.004556:0.004045:0.008803:0.002688:0.002688:0.008735:0.009206
double-blind:@0.571907:0.632584:0.655082:0.632584:0.655082:0.618555:0.571907:0.618555:0.009206:0.008803:0.008171:0.009165:0.002688:0.008735:0.004462:0.009165:0.002688:0.002688:0.008198:0.009206
double-blind, parallel :@0.749949:0.632584:0.892660:0.632584:0.892660:0.618555:0.749949:0.618555:0.009206:0.008803:0.008171:0.009165:0.002688:0.008735:0.004462:0.009165:0.002688:0.002688:0.008198:0.009206:0.003723:0.003723:0.009165:0.009179:0.004045:0.009179:0.002688:0.002688:0.008735:0.002688:0.003723
assignment:@0.749949:0.645412:0.823582:0.645412:0.823582:0.631383:0.749949:0.631383:0.009179:0.005214:0.005214:0.002688:0.009045:0.008198:0.012606:0.008735:0.008198:0.004556
Primary outcome:@0.082051:0.660806:0.193596:0.660806:0.193596:0.646141:0.082051:0.646141:0.007526:0.004301:0.003225:0.012633:0.008870:0.004301:0.007795:0.003763:0.008601:0.008063:0.004032:0.008601:0.008601:0.012633:0.008601
4-point mACe: :@0.215810:0.660806:0.312572:0.660806:0.312572:0.646141:0.215810:0.646141:0.007526:0.005644:0.008870:0.008601:0.003225:0.008063:0.004032:0.003763:0.012095:0.009945:0.010483:0.006988:0.003763:0.003763
CV death, :@0.312559:0.660806:0.383961:0.660806:0.383961:0.646777:0.312559:0.646777:0.010926:0.009434:0.003723:0.009206:0.008735:0.009179:0.004556:0.008198:0.003723:0.003723
non-fatal MI, non-fatal :@0.215810:0.673635:0.365052:0.673635:0.365052:0.659606:0.215810:0.659606:0.008198:0.008803:0.008198:0.004462:0.004220:0.009179:0.004556:0.009179:0.002688:0.003723:0.012351:0.003037:0.003723:0.003723:0.008198:0.008803:0.008198:0.004462:0.004220:0.009179:0.004556:0.009179:0.002688:0.003723
stroke, hospitalisation for :@0.215810:0.686463:0.377685:0.686463:0.377685:0.672434:0.215810:0.672434:0.005214:0.004556:0.004045:0.008803:0.006746:0.008735:0.003723:0.003723:0.008198:0.008803:0.005214:0.009165:0.002688:0.004556:0.009179:0.002688:0.002688:0.005214:0.009179:0.004556:0.002688:0.008803:0.008198:0.003723:0.004220:0.008803:0.004045:0.003723
unstable angina. Non-:@0.215810:0.699291:0.360779:0.699291:0.360779:0.685262:0.215810:0.685262:0.008171:0.008198:0.005214:0.004556:0.009179:0.009165:0.002688:0.008735:0.003723:0.009179:0.008198:0.009045:0.002688:0.008198:0.009179:0.003723:0.003723:0.009945:0.008803:0.008198:0.004462
inferiority and superiority :@0.215810:0.712120:0.376744:0.712120:0.376744:0.698091:0.215810:0.698091:0.002688:0.008198:0.004220:0.008735:0.004045:0.002688:0.008803:0.004045:0.002688:0.004556:0.007203:0.003723:0.009179:0.008198:0.009206:0.003723:0.005214:0.008171:0.009165:0.008735:0.004045:0.002688:0.008803:0.004045:0.002688:0.004556:0.007203:0.003723
design:@0.215810:0.724948:0.258896:0.724948:0.258896:0.710919:0.215810:0.710919:0.009206:0.008735:0.005214:0.002688:0.009045:0.008198
3-point mACe: :@0.393852:0.660806:0.490614:0.660806:0.490614:0.646141:0.393852:0.646141:0.007526:0.005644:0.008870:0.008601:0.003225:0.008063:0.004032:0.003763:0.012095:0.009945:0.010483:0.006988:0.003763:0.003763
CV death, :@0.490601:0.660806:0.562003:0.660806:0.562003:0.646777:0.490601:0.646777:0.010926:0.009434:0.003723:0.009206:0.008735:0.009179:0.004556:0.008198:0.003723:0.003723
non-fatal MI, non-:@0.393852:0.673635:0.509550:0.673635:0.509550:0.659606:0.393852:0.659606:0.008198:0.008803:0.008198:0.004462:0.004220:0.009179:0.004556:0.009179:0.002688:0.003723:0.012351:0.003037:0.003723:0.003723:0.008198:0.008803:0.008198:0.004462
fatal ischaemic stroke. :@0.393852:0.686463:0.543363:0.686463:0.543363:0.672434:0.393852:0.672434:0.004220:0.009179:0.004556:0.009179:0.002688:0.003723:0.002688:0.005214:0.008695:0.008198:0.009179:0.008735:0.012606:0.002688:0.008695:0.003723:0.005214:0.004556:0.004045:0.008803:0.006746:0.008735:0.003723:0.003723
superiority and non-:@0.393852:0.699291:0.524333:0.699291:0.524333:0.685262:0.393852:0.685262:0.006693:0.008171:0.009165:0.008735:0.004045:0.002688:0.008803:0.004045:0.002688:0.004556:0.007203:0.003723:0.009179:0.008198:0.009206:0.003723:0.008198:0.008803:0.008198:0.004462
inferiority design:@0.393852:0.712120:0.498530:0.712120:0.498530:0.698091:0.393852:0.698091:0.002688:0.008198:0.004220:0.008735:0.004045:0.002688:0.008803:0.004045:0.002688:0.004556:0.007203:0.003723:0.009206:0.008735:0.005214:0.002688:0.009045:0.008198
3-point mACe::@0.571894:0.660806:0.664893:0.660806:0.664893:0.646141:0.571894:0.646141:0.007526:0.005644:0.008870:0.008601:0.003225:0.008063:0.004032:0.003763:0.012095:0.009945:0.010483:0.006988:0.003763
 CV death, :@0.664879:0.660806:0.740004:0.660806:0.740004:0.646777:0.664879:0.646777:0.003723:0.010926:0.009434:0.003723:0.009206:0.008735:0.009179:0.004556:0.008198:0.003723:0.003723
non-fatal acute MI, non-:@0.571894:0.673635:0.730651:0.673635:0.730651:0.659606:0.571894:0.659606:0.008198:0.008803:0.008198:0.004462:0.004220:0.009179:0.004556:0.009179:0.002688:0.003723:0.009179:0.008695:0.008171:0.004556:0.008735:0.003723:0.012351:0.003037:0.003723:0.003723:0.008198:0.008803:0.008198:0.004462
fatal stroke. Non-inferiority  stroke, hospitalisation for :@0.571894:0.686463:0.911810:0.686463:0.911810:0.672434:0.571894:0.672434:0.004220:0.009179:0.004556:0.009179:0.002688:0.003534:0.005214:0.004556:0.004045:0.008803:0.006746:0.008735:0.003723:0.003521:0.009945:0.008803:0.008198:0.004448:0.002688:0.008198:0.004220:0.008735:0.004045:0.002688:0.008803:0.004045:0.002688:0.004556:0.007203:0.003723:0.006357:0.005214:0.004556:0.004045:0.008803:0.006746:0.008735:0.003723:0.003723:0.008198:0.008803:0.005214:0.009165:0.002688:0.004556:0.009179:0.002688:0.002688:0.005214:0.009179:0.004556:0.002688:0.008803:0.008198:0.003723:0.004220:0.008803:0.004045:0.003723
design:@0.571894:0.699291:0.614980:0.699291:0.614980:0.685262:0.571894:0.685262:0.009206:0.008735:0.005214:0.002688:0.009045:0.008198
4-point mACe: :@0.749936:0.660806:0.846698:0.660806:0.846698:0.646141:0.749936:0.646141:0.007526:0.005644:0.008870:0.008601:0.003225:0.008063:0.004032:0.003763:0.012095:0.009945:0.010483:0.006988:0.003763:0.003763
CV death, :@0.846684:0.660806:0.918086:0.660806:0.918086:0.646777:0.846684:0.646777:0.010926:0.009434:0.003723:0.009206:0.008735:0.009179:0.004556:0.008198:0.003723:0.003723
non-fatal MI, non-fatal :@0.749936:0.673635:0.899178:0.673635:0.899178:0.659606:0.749936:0.659606:0.008198:0.008803:0.008198:0.004462:0.004220:0.009179:0.004556:0.009179:0.002688:0.003723:0.012351:0.003037:0.003723:0.003723:0.008198:0.008803:0.008198:0.004462:0.004220:0.009179:0.004556:0.009179:0.002688:0.003723
unstable angina:@0.749936:0.699291:0.856051:0.699291:0.856051:0.685262:0.749936:0.685262:0.008171:0.008198:0.005214:0.004556:0.009179:0.009165:0.002688:0.008735:0.003723:0.009179:0.008198:0.009045:0.002688:0.008198:0.009179
results:@0.082037:0.740342:0.125580:0.740342:0.125580:0.725676:0.082037:0.725676:0.007795:0.008601:0.005913:0.008063:0.003225:0.004032:0.005913
primary outcome::@0.215797:0.740342:0.331333:0.740342:0.331333:0.726313:0.215797:0.726313:0.007956:0.004045:0.002688:0.012606:0.009179:0.004045:0.007203:0.003723:0.008803:0.008171:0.004556:0.008695:0.008803:0.012606:0.008735:0.003723
sitagliptin 11.4%, placebo  saxagliptin 7.3%, placebo  alogliptin 11.3%, placebo :@0.215797:0.753170:0.739373:0.753170:0.739373:0.739141:0.215797:0.739141:0.005214:0.002688:0.004556:0.009179:0.009045:0.002688:0.002688:0.009165:0.004556:0.002688:0.008198:0.003723:0.007445:0.007445:0.003723:0.007445:0.010415:0.003723:0.003723:0.009165:0.002688:0.009179:0.008695:0.008735:0.009165:0.008803:0.003723:0.009582:0.005214:0.009179:0.006451:0.009179:0.009045:0.002688:0.002688:0.009165:0.004556:0.002688:0.008198:0.003723:0.007445:0.003723:0.007445:0.010415:0.003723:0.003723:0.009165:0.002688:0.009179:0.008695:0.008735:0.009165:0.008803:0.003723:0.008641:0.009179:0.002688:0.008803:0.009045:0.002688:0.002688:0.009165:0.004556:0.002688:0.008198:0.003723:0.007445:0.007445:0.003723:0.007445:0.010415:0.003723:0.003723:0.009165:0.002688:0.009179:0.008695:0.008735:0.009165:0.008803:0.003723
11.6%, hazard ratio: 0.98 :@0.215797:0.765998:0.375454:0.765998:0.375454:0.751969:0.215797:0.751969:0.007445:0.007445:0.003723:0.007445:0.010415:0.003723:0.003723:0.008198:0.009179:0.005712:0.009179:0.004045:0.009206:0.003723:0.004045:0.009179:0.004556:0.002688:0.008803:0.003723:0.003723:0.007445:0.003723:0.007445:0.007445:0.003723
(95% Cl: 0.88 to 1.09), :@0.215797:0.778827:0.356169:0.778827:0.356169:0.764798:0.215797:0.764798:0.004959:0.007445:0.007445:0.010415:0.003723:0.010926:0.002688:0.003723:0.003723:0.007445:0.003723:0.007445:0.007445:0.003723:0.004556:0.008803:0.003723:0.007445:0.003723:0.007445:0.007445:0.004959:0.003723:0.003723
p <0.001. Secondary :@0.215797:0.791655:0.352258:0.791655:0.352258:0.777626:0.215797:0.777626:0.009165:0.003723:0.008144:0.007445:0.003723:0.007445:0.007445:0.007445:0.003723:0.003723:0.006693:0.008735:0.008695:0.008803:0.008198:0.009206:0.009179:0.004045:0.007203:0.003723
outcome: heart failure :@0.215797:0.804483:0.365496:0.804483:0.365496:0.790454:0.215797:0.790454:0.008803:0.008171:0.004556:0.008695:0.008803:0.012606:0.008735:0.003723:0.003723:0.008198:0.008735:0.009179:0.004045:0.004556:0.003723:0.004220:0.009179:0.002688:0.002688:0.008171:0.004045:0.008735:0.003723
hospitalisation, sitagliptin :@0.215797:0.817311:0.379446:0.817311:0.379446:0.803282:0.215797:0.803282:0.008198:0.008803:0.005214:0.009165:0.002688:0.004556:0.009179:0.002688:0.002688:0.005214:0.009179:0.004556:0.002688:0.008803:0.008198:0.003723:0.003723:0.005214:0.002688:0.004556:0.009179:0.009045:0.002688:0.002688:0.009165:0.004556:0.002688:0.008198:0.003723
2.8%, placebo 2.8%, :@0.215797:0.830140:0.348898:0.830140:0.348898:0.816111:0.215797:0.816111:0.007445:0.003723:0.007445:0.010415:0.003723:0.003723:0.009165:0.002688:0.009179:0.008695:0.008735:0.009165:0.008803:0.003723:0.007445:0.003723:0.007445:0.010415:0.003723:0.003723
hazard ratio: 1.00 (95% Cl:  hazard ratio: 1.27 (95% Cl:  p = 0.66:@0.215797:0.842968:0.622694:0.842968:0.622694:0.828939:0.215797:0.828939:0.008198:0.009179:0.005712:0.009179:0.004045:0.009206:0.003723:0.004045:0.009179:0.004556:0.002688:0.008803:0.003723:0.003723:0.007445:0.003723:0.007445:0.007445:0.003723:0.004959:0.007445:0.007445:0.010415:0.003723:0.010926:0.002688:0.003723:0.003723:0.007257:0.008198:0.009179:0.005712:0.009179:0.004045:0.009206:0.003723:0.004045:0.009179:0.004556:0.002688:0.008803:0.003723:0.003723:0.007445:0.003723:0.007445:0.007445:0.003723:0.004959:0.007445:0.007445:0.010415:0.003723:0.010926:0.002688:0.003723:0.003723:0.007257:0.009165:0.003723:0.008144:0.003723:0.007445:0.003723:0.007445:0.007445
0.83-1.20), p = 0.98:@0.215797:0.855796:0.335594:0.855796:0.335594:0.841767:0.215797:0.841767:0.007445:0.003723:0.007445:0.007445:0.004462:0.007445:0.003723:0.007445:0.007445:0.004959:0.003723:0.003723:0.009165:0.003723:0.008144:0.003723:0.007445:0.003723:0.007445:0.007445
primary outcome: :@0.393839:0.740342:0.513098:0.740342:0.513098:0.726313:0.393839:0.726313:0.007956:0.004045:0.002688:0.012606:0.009179:0.004045:0.007203:0.003723:0.008803:0.008171:0.004556:0.008695:0.008803:0.012606:0.008735:0.003723:0.003723
7.2%, hazard ratio: 1.0 :@0.393839:0.765998:0.538605:0.765998:0.538605:0.751969:0.393839:0.751969:0.007445:0.003723:0.007445:0.010415:0.003723:0.003723:0.008198:0.009179:0.005712:0.009179:0.004045:0.009206:0.003723:0.004045:0.009179:0.004556:0.002688:0.008803:0.003723:0.003723:0.007445:0.003723:0.007445:0.003723
(95% Cl: 0.89-1.12), :@0.393839:0.778827:0.517869:0.778827:0.517869:0.764798:0.393839:0.764798:0.004959:0.007445:0.007445:0.010415:0.003723:0.010926:0.002688:0.003723:0.003723:0.007445:0.003723:0.007445:0.007445:0.004462:0.007445:0.003723:0.007445:0.007445:0.004959:0.003723:0.003723
p = 0.99. secondary :@0.393839:0.791655:0.526577:0.791655:0.526577:0.777626:0.393839:0.777626:0.009165:0.003723:0.008144:0.003723:0.007445:0.003723:0.007445:0.007445:0.003723:0.003723:0.006693:0.008735:0.008695:0.008803:0.008198:0.009206:0.009179:0.004045:0.007203:0.003723
outcome, heart failure :@0.393839:0.804483:0.543537:0.804483:0.543537:0.790454:0.393839:0.790454:0.008803:0.008171:0.004556:0.008695:0.008803:0.012606:0.008735:0.003723:0.003723:0.008198:0.008735:0.009179:0.004045:0.004556:0.003723:0.004220:0.009179:0.002688:0.002688:0.008171:0.004045:0.008735:0.003723
hospitalisation: saxagliptin  2.9%, hazard ratio: 1.07 :@0.393839:0.817311:0.724092:0.817311:0.724092:0.803282:0.393839:0.803282:0.008198:0.008803:0.005214:0.009165:0.002688:0.004556:0.009179:0.002688:0.002688:0.005214:0.009179:0.004556:0.002688:0.008803:0.008198:0.003723:0.003373:0.005214:0.009179:0.006451:0.009179:0.009045:0.002688:0.002688:0.009165:0.004556:0.002688:0.008198:0.003723:0.006357:0.007445:0.003723:0.007445:0.010415:0.003723:0.003723:0.008198:0.009179:0.005712:0.009179:0.004045:0.009206:0.003723:0.004045:0.009179:0.004556:0.002688:0.008803:0.003723:0.003723:0.007445:0.003723:0.007445:0.007445:0.003723
3.5%, placebo 2.8%, :@0.393839:0.830140:0.526940:0.830140:0.526940:0.816111:0.393839:0.816111:0.007445:0.003723:0.007445:0.010415:0.003723:0.003723:0.009165:0.002688:0.009179:0.008695:0.008735:0.009165:0.008803:0.003723:0.007445:0.003723:0.007445:0.010415:0.003723:0.003723
1.07-1.51), p = 0.007:@0.393839:0.855796:0.521081:0.855796:0.521081:0.841767:0.393839:0.841767:0.007445:0.003723:0.007445:0.007445:0.004462:0.007445:0.003723:0.007445:0.007445:0.004959:0.003723:0.003723:0.009165:0.003723:0.008144:0.003723:0.007445:0.003723:0.007445:0.007445:0.007445
primary outcome: :@0.571881:0.740342:0.691140:0.740342:0.691140:0.726313:0.571881:0.726313:0.007956:0.004045:0.002688:0.012606:0.009179:0.004045:0.007203:0.003723:0.008803:0.008171:0.004556:0.008695:0.008803:0.012606:0.008735:0.003723:0.003723
11.8%, hazard ratio: 0.96 :@0.571881:0.765998:0.731538:0.765998:0.731538:0.751969:0.571881:0.751969:0.007445:0.007445:0.003723:0.007445:0.010415:0.003723:0.003723:0.008198:0.009179:0.005712:0.009179:0.004045:0.009206:0.003723:0.004045:0.009179:0.004556:0.002688:0.008803:0.003723:0.003723:0.007445:0.003723:0.007445:0.007445:0.003723
(95%Cl: <1.16), p = 0.32. :@0.571881:0.778827:0.728070:0.778827:0.728070:0.764798:0.571881:0.764798:0.004959:0.007445:0.007445:0.010415:0.010926:0.002688:0.003723:0.003723:0.008144:0.007445:0.003723:0.007445:0.007445:0.004959:0.003723:0.003723:0.009165:0.003723:0.008144:0.003723:0.007445:0.003723:0.007445:0.007445:0.003723:0.003723
post hoc analysis: :@0.571881:0.791655:0.688559:0.791655:0.688559:0.777626:0.571881:0.777626:0.007956:0.008803:0.005214:0.004556:0.003723:0.008198:0.008803:0.008695:0.003723:0.009179:0.008198:0.009179:0.002688:0.007203:0.005214:0.002688:0.005214:0.003723:0.003723
alogliptin 3.1%, placebo :@0.571881:0.804483:0.731927:0.804483:0.731927:0.790454:0.571881:0.790454:0.009179:0.002688:0.008803:0.009045:0.002688:0.002688:0.009165:0.004556:0.002688:0.008198:0.003723:0.007445:0.003723:0.007445:0.010415:0.003723:0.003723:0.009165:0.002688:0.009179:0.008695:0.008735:0.009165:0.008803:0.003723
(95% Cl: 0.79-1.46), :@0.571881:0.830140:0.695910:0.830140:0.695910:0.816111:0.571881:0.816111:0.004959:0.007445:0.007445:0.010415:0.003723:0.010926:0.002688:0.003723:0.003723:0.007445:0.003723:0.007445:0.007445:0.004462:0.007445:0.003723:0.007445:0.007445:0.004959:0.003723:0.003723
Ongoing:@0.749922:0.740342:0.807576:0.740342:0.807576:0.726313:0.749922:0.726313:0.011679:0.008198:0.009045:0.008803:0.002688:0.008198:0.009045
Additional :@0.082024:0.871190:0.152714:0.871190:0.152714:0.856525:0.082024:0.856525:0.009945:0.008870:0.008870:0.003225:0.004032:0.003225:0.008601:0.008063:0.008870:0.003225:0.003763
benefits/risks:@0.082024:0.884018:0.166422:0.884018:0.166422:0.869353:0.082024:0.869353:0.008870:0.008601:0.008063:0.008601:0.003494:0.003494:0.004032:0.005913:0.006182:0.004301:0.003225:0.005913:0.007795:0.005913
AT 4 months, HbA1c 0.4 :@0.215784:0.871190:0.371852:0.871190:0.371852:0.857161:0.215784:0.857161:0.009945:0.005725:0.003723:0.007445:0.003723:0.012606:0.008803:0.008198:0.004556:0.008198:0.005214:0.003723:0.003723:0.009179:0.009165:0.009945:0.007445:0.008695:0.003723:0.007445:0.003723:0.007445:0.003723
percentage points lower :@0.215784:0.884018:0.380104:0.884018:0.380104:0.869989:0.215784:0.869989:0.009165:0.008735:0.004045:0.008695:0.008735:0.008198:0.004556:0.009179:0.009045:0.008735:0.003723:0.009165:0.008803:0.002688:0.008198:0.004556:0.005214:0.003723:0.002688:0.008803:0.011168:0.008735:0.004045:0.003723
in sitagliptin group   :@0.215784:0.896847:0.354113:0.896847:0.354113:0.882818:0.215784:0.882818:0.002688:0.008198:0.003723:0.005214:0.002688:0.004556:0.009179:0.009045:0.002688:0.002688:0.009165:0.004556:0.002688:0.008198:0.003723:0.009045:0.004045:0.008803:0.008171:0.009165:0.003723:0.012660:0.003723
vs:@0.337730:0.896847:0.350390:0.896847:0.350390:0.882818:0.337730:0.882818:0.007445:0.005214
placebo group; sitagliptin :@0.215784:0.909675:0.386998:0.909675:0.386998:0.895646:0.215784:0.895646:0.009165:0.002688:0.009179:0.008695:0.008735:0.009165:0.008803:0.003723:0.009045:0.004045:0.008803:0.008171:0.009165:0.003723:0.003723:0.005214:0.002688:0.004556:0.009179:0.009045:0.002688:0.002688:0.009165:0.004556:0.002688:0.008198:0.003723
group less likely to start :@0.215784:0.922503:0.367135:0.922503:0.367135:0.908474:0.215784:0.908474:0.009045:0.004045:0.008803:0.008171:0.009165:0.003723:0.002688:0.008735:0.005214:0.005214:0.003723:0.002688:0.002688:0.006746:0.008735:0.002688:0.007203:0.003723:0.004556:0.008803:0.003723:0.005214:0.004556:0.009179:0.004045:0.004556:0.003723
long-term insulin therapy:@0.215784:0.935332:0.375293:0.935332:0.375293:0.921303:0.215784:0.921303:0.002688:0.008803:0.008198:0.009045:0.004462:0.004556:0.008735:0.004045:0.012606:0.003723:0.002688:0.008198:0.005214:0.008171:0.002688:0.002688:0.008198:0.003723:0.004556:0.008198:0.008735:0.004045:0.009179:0.009165:0.007203
Glycaemic control was :@0.393825:0.871190:0.548550:0.871190:0.548550:0.857161:0.393825:0.857161:0.011719:0.002688:0.007203:0.008695:0.009179:0.008735:0.012606:0.002688:0.008695:0.003723:0.008695:0.008803:0.008198:0.004556:0.004045:0.008803:0.002688:0.003723:0.011168:0.009179:0.005214:0.003723
lower in saxagliptin group :@0.393825:0.884018:0.563320:0.884018:0.563320:0.869989:0.393825:0.869989:0.002688:0.008803:0.011168:0.008735:0.004045:0.003723:0.002688:0.008198:0.003723:0.005214:0.009179:0.006451:0.009179:0.009045:0.002688:0.002688:0.009165:0.004556:0.002688:0.008198:0.003723:0.009045:0.004045:0.008803:0.008171:0.009165:0.003723
compared to placebo:@0.393825:0.896847:0.541495:0.896847:0.541495:0.882818:0.393825:0.882818:0.008695:0.008803:0.012606:0.009165:0.009179:0.004045:0.008735:0.009206:0.003723:0.004556:0.008803:0.003723:0.009165:0.002688:0.009179:0.008695:0.008735:0.009165:0.008803
NT-pro-BNp concentrations :@0.571867:0.871190:0.743579:0.871190:0.743579:0.857161:0.571867:0.857161:0.009676:0.005456:0.004193:0.008897:0.003776:0.008534:0.004193:0.007445:0.009676:0.007687:0.003387:0.008426:0.008534:0.007929:0.008426:0.008467:0.007929:0.004287:0.003776:0.008910:0.004287:0.002419:0.008534:0.007929:0.005214:0.003723
decreased significantly :@0.571867:0.884018:0.720316:0.884018:0.720316:0.869989:0.571867:0.869989:0.008937:0.008467:0.008426:0.003776:0.008467:0.008910:0.004946:0.008467:0.008937:0.003454:0.004946:0.002419:0.008776:0.007929:0.002419:0.003138:0.003138:0.008426:0.008910:0.007929:0.004287:0.002419:0.007203:0.003723
and similar in the 2 groups. :@0.571867:0.896847:0.740623:0.896847:0.740623:0.882818:0.571867:0.882818:0.008910:0.007929:0.008937:0.003454:0.004946:0.002419:0.012337:0.002419:0.002419:0.008910:0.003776:0.003454:0.002419:0.007929:0.003454:0.004287:0.007929:0.008467:0.003454:0.007177:0.003454:0.008776:0.003776:0.008534:0.007902:0.008897:0.004946:0.003723:0.003723
post-hoc analysis for :@0.571867:0.909675:0.700977:0.909675:0.700977:0.895646:0.571867:0.895646:0.007687:0.008534:0.004946:0.004287:0.004193:0.007929:0.008534:0.008426:0.003454:0.008910:0.007929:0.008910:0.002419:0.006935:0.004946:0.002419:0.004946:0.003454:0.003951:0.008534:0.004045:0.003723
hospitalisation for heart :@0.571867:0.922503:0.720182:0.922503:0.720182:0.908474:0.571867:0.908474:0.007929:0.008534:0.004946:0.008897:0.002419:0.004287:0.008910:0.002419:0.002419:0.004946:0.008910:0.004287:0.002419:0.008534:0.007929:0.003454:0.003951:0.008534:0.003776:0.003454:0.007929:0.008467:0.008910:0.003776:0.004556:0.003723
failure:@0.571867:0.935332:0.609981:0.935332:0.609981:0.921303:0.571867:0.921303:0.003951:0.008910:0.002419:0.002419:0.007902:0.003776:0.008735
table 2. summarised abstracts of DPP-4 inhibitor studies:@0.076190:0.526780:0.479566:0.526780:0.479566:0.510281:0.076190:0.510281:0.006350:0.009979:0.009979:0.003629:0.009676:0.004233:0.008467:0.004233:0.004233:0.007862:0.009071:0.014212:0.014212:0.009979:0.004838:0.003629:0.006652:0.009676:0.009979:0.004233:0.009979:0.009979:0.006652:0.004536:0.004838:0.009979:0.009676:0.004536:0.006652:0.004233:0.009676:0.004233:0.004233:0.010583:0.008467:0.008467:0.006350:0.008467:0.004233:0.003629:0.009071:0.009071:0.003629:0.009979:0.003629:0.004536:0.009676:0.004838:0.004233:0.006652:0.004536:0.009071:0.009979:0.003629:0.009676:0.006652
DPP-4 enzyme:@0.246769:0.089783:0.342887:0.089783:0.342887:0.075481:0.246769:0.075481:0.010484:0.008580:0.008350:0.004835:0.008227:0.003177:0.007920:0.008780:0.007153:0.007675:0.013016:0.007920
inactivates GLP-1:@0.237651:0.100316:0.352005:0.100316:0.352005:0.086015:0.237651:0.086015:0.003929:0.008780:0.007798:0.007122:0.005388:0.003929:0.007706:0.007706:0.005296:0.007920:0.006401:0.003177:0.010223:0.007567:0.008350:0.004835:0.008227
Food:@0.075268:0.161174:0.108884:0.161174:0.108884:0.146873:0.075268:0.146873:0.007383:0.008657:0.008657:0.008918
GLP-1:@0.275227:0.184067:0.314429:0.184067:0.314429:0.169765:0.275227:0.169765:0.010223:0.007567:0.008350:0.004835:0.008227
X:@0.288257:0.140453:0.301021:0.140453:0.301021:0.120430:0.288257:0.120430:0.012765
Small :@0.159713:0.208689:0.199561:0.208689:0.199561:0.194387:0.159713:0.194387:0.007966:0.013016:0.007798:0.003945:0.003945:0.003177
intestine:@0.148923:0.219222:0.207189:0.219222:0.207189:0.204921:0.148923:0.204921:0.003929:0.008703:0.005296:0.007920:0.006401:0.005388:0.003929:0.008780:0.007920
DPP-4:@0.320116:0.122060:0.360592:0.122060:0.360592:0.107758:0.320116:0.107758:0.010484:0.008580:0.008350:0.004835:0.008227
inhibitors:@0.308281:0.132593:0.372427:0.132593:0.372427:0.118291:0.308281:0.118291:0.003929:0.008780:0.008780:0.003929:0.008980:0.003929:0.005296:0.008657:0.005464:0.006401
block the:@0.309586:0.143126:0.371138:0.143126:0.371138:0.128824:0.309586:0.128824:0.008980:0.003945:0.008657:0.006892:0.007813:0.003177:0.005388:0.008780:0.007920
DPP-4:@0.320116:0.153659:0.360592:0.153659:0.360592:0.139358:0.320116:0.139358:0.010484:0.008580:0.008350:0.004835:0.008227
enzyme:@0.314114:0.164192:0.366579:0.164192:0.366579:0.149891:0.314114:0.149891:0.007920:0.008780:0.007153:0.007675:0.013016:0.007920
Stimulates:@0.400501:0.147480:0.470741:0.147480:0.470741:0.133178:0.400501:0.133178:0.007905:0.005388:0.003929:0.013016:0.008734:0.003945:0.007706:0.005296:0.007920:0.006401
insulin:@0.413380:0.158013:0.457878:0.158013:0.457878:0.143711:0.413380:0.143711:0.003929:0.008780:0.006401:0.008734:0.003945:0.003929:0.008780
secretion:@0.405014:0.168546:0.466228:0.168546:0.466228:0.154244:0.405014:0.154244:0.006401:0.007920:0.006892:0.005326:0.007920:0.005388:0.003929:0.008657:0.008780
Suppresses:@0.390647:0.197021:0.465675:0.197021:0.465675:0.182719:0.390647:0.182719:0.007966:0.008734:0.008980:0.008980:0.005326:0.007920:0.006401:0.006401:0.007920:0.006401
glucagon:@0.396956:0.207554:0.459351:0.207554:0.459351:0.193252:0.396956:0.193252:0.008795:0.003945:0.008734:0.006892:0.007798:0.008795:0.008657:0.008780
secretion:@0.397554:0.218087:0.458768:0.218087:0.458768:0.203785:0.397554:0.203785:0.006401:0.007920:0.006892:0.005326:0.007920:0.005388:0.003929:0.008657:0.008780
figure 1. mechanism of action of DPP-4 inhibitors:@0.076190:0.249307:0.429976:0.249307:0.429976:0.232809:0.076190:0.232809:0.007257:0.003629:0.009979:0.009071:0.004838:0.009676:0.004233:0.008467:0.004233:0.004233:0.013607:0.009676:0.009676:0.009071:0.009979:0.009071:0.003629:0.006652:0.014212:0.004233:0.009676:0.004233:0.004233:0.009979:0.009676:0.004536:0.003629:0.009676:0.009071:0.004233:0.009676:0.004233:0.004233:0.010583:0.008467:0.008467:0.006350:0.008467:0.004233:0.003629:0.009071:0.009071:0.003629:0.009979:0.003629:0.004536:0.009676:0.004838:0.006652
Drucker DJ. :@0.076190:0.229526:0.124067:0.229526:0.124067:0.220757:0.076190:0.220757:0.006165:0.002444:0.005023:0.005350:0.004133:0.005376:0.002444:0.002243:0.006165:0.003965:0.002243:0.002327
Diabetes Care.:@0.123983:0.229526:0.184518:0.229526:0.184518:0.220757:0.123983:0.220757:0.006165:0.001596:0.005653:0.005644:0.005376:0.002763:0.005376:0.003175:0.002243:0.006745:0.005653:0.002444:0.005376:0.002327
 2007;30:1335-1343.:@0.184434:0.229526:0.260164:0.229526:0.260164:0.220757:0.184434:0.220757:0.002243:0.004569:0.004569:0.004569:0.004569:0.002243:0.004569:0.004569:0.002243:0.004569:0.004569:0.004569:0.004569:0.002705:0.004569:0.004569:0.004569:0.004569:0.002327
Vellanki p, Davis G. Cardiovascular Outcomes of Dpp-4 Inhibitors. Endocrineweb. 2016;7:3:@0.076190:0.946357:0.425860:0.946357:0.425860:0.937589:0.076190:0.937589:0.005896:0.005460:0.001680:0.001680:0.005737:0.005124:0.004217:0.001680:0.002327:0.004972:0.002327:0.002327:0.006249:0.005737:0.004653:0.001680:0.003259:0.002327:0.007324:0.002327:0.002327:0.006644:0.005552:0.002343:0.005569:0.001495:0.005317:0.004469:0.005552:0.003074:0.005250:0.004922:0.001495:0.005552:0.002343:0.002142:0.007114:0.004922:0.002663:0.005250:0.005317:0.007694:0.005275:0.003074:0.002142:0.005317:0.002453:0.002142:0.006064:0.004788:0.004788:0.002604:0.004469:0.002142:0.001713:0.004939:0.004939:0.001495:0.005544:0.001495:0.002663:0.005317:0.002343:0.003074:0.002142:0.002142:0.004317:0.004939:0.005569:0.005317:0.005250:0.002343:0.001495:0.004939:0.005275:0.006795:0.005275:0.005544:0.002142:0.002142:0.004469:0.004469:0.004469:0.004469:0.002142:0.004469:0.002142:0.004653